Better AAV therapeutics
The promise of AAV gene therapy comes with an obligation to solve the complicated issue of supplying viral-based gene therapies on a global scale. AAV manufacturing is highly complex and historically inefficient with a cost of goods that pushes the purchase of therapeutics into the millions of dollars. We recognized this issue more than a decade ago and focused on creating robust, scalable manufacturing capabilities. The result was Pro10™ technology and joint ventures to create world-class GMP manufacturing facilities.
Clinical and commercial AAV manufacturing
Together with Columbus Venture Partners, AskBio operates Viralgen, a cGMP manufacturing facility. The Viralgen Vector Core uses our Pro10™ technology to manufacture AAV in a state-of-the-art facility for use in human gene therapy clinical trials. An expansion for high-volume commercial AAV manufacturing is currently underway. Viralgen offers what we believe is the most flexible, scalable AAV manufacturing system in the industry.
We continue to invest in innovative AAV manufacturing as a partner in Viralgen, a focused CDMO organization. We continue to set the industry standard for scalable, reliable and efficient manufacturing to help drive down cost and expand patient access to life-changing therapies.
“We must ensure gene therapy can be equally accessible, even to those with ultra-rare diseases. Large-scale, efficient manufacturing of AAV product is critical.”
R. Jude Samulski, PhD
Chief Scientific Officer and Co-Founder